Early On-Set CRC: A Biologically Distinct Threat? - Part II

03/15/2021

In part 2 of this video series, Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center, New York, discusses the clinical findings, molecular drivers/alterations, and conducting further research for "Early On-Set Colorectal Cancer: A Biologically Distinct Threat?" presented at the 2021 Great Debates & Updates in Gastrointestinal Malignancies meeting.

Recent News

News

Pirtobrutinib Demonstrates Promising Efficacy, Safety Among Patients With B-Cell Malignancies With Richter Transformation

09/06/2024

Amber Denham ;

Pirtobrutinib treatment shows encouraging safety and activity among patients with relapsed/refractory B-cell malignancies who experience Richter transformation, according to a subgroup analysis from the phase 1/2 BRUIN study.

Pirtobrutinib treatment shows...

09/06/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland ;

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission

08/30/2024

Amber Denham ;

According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...

According to results from a...

08/30/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to results from the...

08/30/2024

Oncology

News

Revumenib Demonstrates Clinical Benefit Among Patients With High-Risk, R/R KMT2Ar Acute Leukemia

08/30/2024

Amber Denham ;

According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory...

According to phase 1/2 results...

08/30/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

Sovleplenib, a novel spleen...

08/29/2024

Oncology

News

Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer

08/29/2024

Stephanie Holland ;

According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.

According to results from a...

08/29/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology